ABL has over 50 years of experience partnering with clients to meet their preclinical drug development goals. We provide services to clients with the goal

ABL was established over 50 years ago as a government contractor. We are currently managing hundreds of millions of dollars in contracts in the biotechnology

The Luminex xMAP technology offers significant advantages over traditional bioassays by offering high-throughput multiplexing of up to 100 analytes in a single well of a

Ultrasensitive biomarker detection combined with multiplexing Download

We offer an array of MSD-based immunoassays with a proven increase in both dynamic range and sensitivity, made possible through electrochemiluminescent labeling. Download

Flow cytometric analysis of tumor-associated macrophages is performed by our scientists through the use of cell-specific antibodies plus positive and negative magnetic bead-based cell isolation.

Lymphoproliferation is one of the classic assessments of lymphocyte response to in vitro stimulation. Download

Using peripheral blood mononuclear cells (PBMC) for cell-based immunological assays is a powerful tool to understand and characterize immune mechanisms related to immunotherapies. To address

Fully Automated, Ultrasensitive Detection of Analytes Download

ABL scientists successfully conducted this standardized testing on a large cohort of clinical samples over 3 years, generating up to 350 data points per patient

ABLu2019s step-wise approach is performed systematically and can be adapted to our partnersu2019 needs. The use of state-of-the-art technology and fit-for-purpose validated bio-analytical methods strengthens

Recent preclinical studies have demonstrated the use of properly folded trimeric HIV-1 envelope proteins in eliciting broadly neutralizing antibodies (bNAbs). These bNAbs target highly conserved